Subcutaneous IgG in neurologic diseases

Immunotherapy

Volumn 6, Issue 1, 2014, Pages 71-83

  Berger, Melvin ^a,b  

^a CSL Behring LLC   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

adverse events; chronic idiopathic demyelinating polyneuropathy; IgG; intravenous IgG; mechanism of action; multifocal motor neuropathy; myositis; neuropathy; pharmacokinetics; subcutaneous IgG

Indexed keywords

IMMUNOGLOBULIN G;

ADVERSE DRUG REACTION; CHRONIC IDIOPATHIC DEMYELINATING POLYNEUROPATHY; DRUG MECHANISM; HUMAN; MOTOR NEUROPATHY; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; PHARMACOECONOMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS IMMUNOTHERAPY;

AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; SELF ADMINISTRATION; TREATMENT OUTCOME;

EID: 84896514249     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.146     Document Type: Review

References (73)

1. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin. Immunol. 112, 1-7 (2004).
2. Torgerson TR. Overview of routes of IgG administration. J. Clin. Immunol. 33(Suppl. 2), S87-S89 (2013).
3. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol. Allergy Clin. North Am. 28, 803-819 (2008).
4. Berger M. Subcutaneous administration of IgG. Immunol. Allergy Clin. North Am. 28, 779-802 (2008).
5. Ballow M. Clinical and investigational considerations for the use of IGIV therapy. Am. J. Health Syst. Pharm. 62(6 Suppl. 3), S12-S18 (2005).
6. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus. Med. Rev. 17(4), 241-251 (2003).
7. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus. Med. Rev. 27, 171-178 (2013).
8. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44, 223-226 (1994).
9. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr. Opin. Allergy Clin. Immunol. 6, 434-442 (2006).
10. Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immune deficiency diseases receiving subcutaneous IgG self-infusions at home. J. Clin. Immunol. 26, 65-72 (2006).
11. Waldmann TA, Strober W. Metabolism of immunoglobulins. Prog. Allergy 13, 1-110 (1969).
12. Ritz P, Vol S, Berrut G, Tack I, Arnaud MJ, Tichet J. Influence of gender and body composition on hydration and body water spaces. Clin. Nutr. 27, 740-746 (2008).
13. Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin. Exp. Immunol. 173, 365-371 (2013).
14. Brambell FW, Hemmings, Morris IG. A theoretical model of gamma-globulin catabolism. Nature 203, 1352-1354 (1964).
15. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta-2- microgloblin containing neonatal intestinal transport receptor. Proc. Natl Acad. Sci. USA 93, 5512-5516 (1996).
16. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin. Immunol. 139, 133-141 (2011).
17. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG versus intravenous IgG and selecting an optimal dose. Curr. Opin. Allergy Clin. Immunol. 11, 532-538 (2011).
18. Borte M, Quinti I, Soresina A et al. Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J. Clin. Immunol. 31, 952-961 (2011).
19. Kuitwaard K, van Doorn PA, Vermeulen M et al. Serum IgG levels in intravenous immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J. Neurol. Neurosurg. Psychiatry 84, 859-861 (2013).
20. Berger M, Jolles S, Orange JS, Sleasman JW. Bioavailability of IgG administered by the subcutaneous route. J. Clin. Immunol. 33, 984-990 (2013).
21. Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J. Allergy Clin. Immunol. 127, 315-323 (2011).
22. Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N. Engl. J. Med. 367, 2015-2025 (2012).
23. Quick A, Tandan R. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr. Rheumatol. Rep. 13, 192-198 (2011).
24. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J. Clin. Invest. 94, 1729-1735 (1994).
25. van Doorn PA, Kuitwaard K, Walgaard C et al. IVIG treatment and prognosis in Guillain-Barré syndrome. J. Clin. Immunol. 30(Suppl. 1), S74-S78 (2010).
26. Rajabally YA, Wong SL, Kearney DA. Immunoglobulin G level variations in treated chronic inflammatory demyelinating polyneuropathy: clues for future treatment regimens? J. Neurol. 260(8), 2052-2056 (2013).
27. Press R, Nennesmo I, Kouwenhoven M et al. Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J. Neuroimmunol. 159, 165-176 (2005).
28. Pollard JD, Armati PJ. CIDP - the relevance of recent advances in Schwann cell/axonal neurobiology. J. Peripher. Nerv. Syst. 16, 15-23 (2011).
29. Boerio D, Creange A, Hogrel JY et al. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy. J. Neurol. Sci. 292, 63-71 (2010).
30. Lin CS, Krishnan AV, Park SB, Kiernan MC. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Arch. Neurol. 68, 862-869 (2011).
31. Broyles R, Rodden L, Riley P, Berger M. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders. Postgrad. Med. 125, 65-72 (2013).
32. Mathey EK, Pollard JD. Chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 333, 37-42 (2013).
33. Peltier AC, Donofrio PD. Chronic inflammatory demyelinating polyradiculoneuropathy: from bench to bedside. Semin. Neurol. 32, 187-195 (2012).
34. Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7, 136-144 (2008).
35. Léger JM, De Bleecker JL, Sommer C et al.; PRIMA study investigators. Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study). J. Peripher. Nerv. Syst. 18, 130-140 (2013).
36. Nobile-Orazio E, Cocito D, Jann S et al.; IMC Trial Group. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 11, 493-502 (2012).
37. Latov N, Deng C, Dalakas MC et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neurol. 67, 802-807 (2010).
38. Harbo T, Andersen H, Jakobsen J. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 39, 439-447 (2009).
39. Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio E. How long is IVIg effective in multifocal motor neuropathy? Neurology 62, 666-668 (2004).
40. Markvardsen LH, Debost JC, Harbo T et al.; Danish CIDP and MMN Study Group. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy. Eur. J. Neurol. 20, 836-842 (2013).
41. Lee DH, Linker RA, Paulus W et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37, 406-409 (2008).
42. Cocito D, Serra G, Falcone Y, Paolasso I. The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J. Peripher. Nerv. Syst. 16, 150-152 (2011).
43. Cocito D, Serra G, Paolasso I, Barilã DA, Lopiano L, Cattel L. Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies. J. Peripher. Nerv. Syst. 17, 426-428 (2012).
44. Bayas A, Gold R, Naumann M. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions. J. Neurol. Sci. 324, 53-56 (2013).
45. Muley SA, Parry GJ. Multifocal motor neuropathy. J. Clin. Neurosci. 9, 1201-1209 (2012).
46. Vlam L, van den Berg LH, Cats EA, Piepers S, van der Pol WL. Immune pathogenesis and treatment of multifocal motor neuropathy. J. Clin. Immunol. 33(Suppl. 1), S38-S42 (2013).
47. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. J. Peripher. Nerv. Syst. 15, 295-301 (2010).
48. Dimberg EL. Treatment of multifocal motor neuropathy with immunoglobulin: does route of administration matter? Eur. J. Neurol. 16, 553-554 (2009).
49. Koller H, Schroeter M, Feischen H, Hartung HP, Kieseier BC. Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies. J. Neurol. 253, 1505-1506 (2006).
50. Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur. J. Neurol. 16, 631-638 (2009).
51. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology 75, 1377-1380 (2010).
52. Dacci P, Riva N, Scarlato M et al. Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report. Neurol. Sci. 31, 829-831 (2010).
53. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J. Peripher. Nerv. Syst. 14, 93-100 (2009).
54. Misbah SA, Baumann A, Fazio R et al. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy: an open-label proof-of-concept study. J. Peripher. Nerv. Syst. 16, 92-97 (2011).
55. Vucic S, Black KR, Chong PST, Cros D. Multifocal Motor Neuropathy. Decrease in conduction blocks and reinnervation with long-term IVIG. Neurology 63, 1264-1269 (2004).
56. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst. Rev. 12, CD002277 (2012).
57. Donofrio PD, Berger A, Brannagan TH 3rd et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve 40, 890-900 (2009).
58. Goebel A. Immunoglobulin responsive chronic pain. J. Clin. Immunol. 30(Suppl. 1), S103-S108 (2010).
59. Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 28, 65-72 (2013).
60. Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr. Treat. Options Neurol. 13, 311-323 (2011).
61. Schleinitz N, Jean E, Benarous L et al. Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis? Clin. Rheumatol. 27, 1067-1068 (2008).
62. Danieli MG, Moretti R, Pettinari L, Gabrielli A. Subcutaneous immunoglobulins in ocular myositis. Rheumatology (Oxford) 51, 764-765 (2012).
63. Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun. Rev. 10, 144-149 (2011).
64. Pars K, Garde N, Skripuletz T, Pul R, Dengler R, Stangel M. Subcutaneous immunoglobulin treatment of inclusion body myositis stabilizes dysphagia. Muscle Nerve 48(5), 838-839 (2013).
65. Ochs HD, Gupta S, Kiessling P et al.; Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J. Clin. Immunol. 26, 265-273 (2006).
66. Wasserman RL. Common infusion-related reactions to subcutaneous immunoglobulin therapy: managing patient expectations. Patient Prefer. Adherence 2, 163-166 (2008).
67. Stein MR, Koterba A, Rodden L, Berger M. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad. Med. 123, 186-193 (2011).
68. Gardulf A, Andersen V, Björkander J et al. Subcutaneous imunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 345, 365-369 (1995).
69. Wasserman RL, Melamed I, Stein MR et al.; IGSC 10% with rHuPH20 Study Group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy Clin. Immunol. 130, 951-957 (2012).
70. Von Behring E. Serum therapy in therapeutics and medical science. Nobel Lecture 1901. www.nobelprize.org/nobel-prizes/medicine/ laureates/1901/behring- lecture.html (Accessed 15 November 2013)
71. US Immune Deficiency Foundation. Primary Immunodeficiency Diseases in America: 2003. The first national survey of patients. (Q31a). http://primaryimmune.org/wp-content/ uploads/2011/04/Treatment-Experiences-and- Preferences-of-Patients-with-Primary- Immune-Deficiency-Disease-First-National- Survey-2002.pdf (Accessed 15 November 2013)
72. Chronic inflammatory demyelinating polyneuropathy (CIDP) and treatment with subcutaneous immunoglobulin (IgPro20). http://clinicaltrials.gov/show/ NCT01545076 (Accessed 15 November 2013)
73. ClinicalTrials.gov. www.clinicaltrials.gov (Accessed 15 November 2013)